Compare MLCI & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | LITS |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 36.3M |
| IPO Year | 2026 | 2003 |
| Metric | MLCI | LITS |
|---|---|---|
| Price | $3.07 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.4K | ★ 257.2K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $53,566,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.24 | N/A |
| P/E Ratio | ★ N/A | $1.75 |
| Revenue Growth | ★ 7.58 | N/A |
| 52 Week Low | $2.56 | $0.69 |
| 52 Week High | $8.68 | $1.99 |
| Indicator | MLCI | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 36.24 |
| Support Level | $2.65 | $0.74 |
| Resistance Level | $3.22 | $1.24 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 30.77 | 20.65 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.